These six proteins (Table 3, shown in bold) were selected for further validation, wherein except VDBP, all candidate biomarkers showed potential to discriminate the healthy control group from the patients and the pre-treatment cases from the post-treatment CP-CML group. The gene discussed is GC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.